FDA approved IMBRUVICA (ibrutinib) plus Rituximab for ttreatment of patients with CLL
On Apr. 21, 2020, the Janssen Pharmaceutical Companies of Johnson & Johnson announced U.S. Food and Drug Administration (FDA) approval of IMBRUVICA (ibrutinib) in combination with rituximab for the treatment of patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who are new to therapy. The approval was based on positive results from the landmark Phase 3 E1912 study that was designed and conducted by
The ECOG-ACRIN Cancer Research Group and sponsored by the National Cancer Institute. This was the 11th FDA approval for IMBRUVICA across six disease areas and is the sixth approval for IMBRUVICA in CLL.
Tags:
Source: U.S. Food and Drug Administration
Credit: microscopy: aA Wright’s stained bone marrow aspirate smear of patient with precursor B-cell acute lymphoblastic leukemia., courtesy Wikipedia.
